sven_abend

Lonza adds executive committee member

pharmafile | June 12, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Lonza, sven Abend 

Sven Abend is joining Swiss chemicals and biotech giant Lonza to serve on its executive committee.

From July Abend will be responsible for corporate strategy and business development at the firm, and he joins Lonza from a chief executive role at fellow Swiss chemical company Kolb.

Beat In-Albon is to remain as Lonza’s chief operating officer for its Specialty Ingredients segment, and will work closely with Abend to ensure alignment of this unit.  

“Sven has a strong track record in establishing sustainable, profitable growth in challenging specialty markets,” says Richard Ridinger, chief executive of Lonza. “His market-driven approach to business will align and reinforce our strategic goals for global growth. We’ll benefit from Sven’s scientific background and diverse experience in supplying chemicals and ingredients to fast-moving consumer goods markets and various industrial markets.”  

Abend began his career as a scientist with Unilever’s Home & Personal Care division. After moving to Cognis, he advanced into positions of broader responsibilities, including roles in product and portfolio management and global key account management. At Kolb he was appointed chief executive in 2012.  

Related Content

Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn

Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …

Lonza to acquire Synaffix to strengthen ADC development

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has …

moderna_norwood_plant

Moderna submits BLA with FDA for COVID vaccine

Moderna has initiated the rolling submission process with the FDA for a Biologics License Application …

Latest content